SRR650201
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.440
- MYC_TARGETS_V2+0.440
- PROTEIN_SECRETION+0.420
- DNA_REPAIR+0.280
- INTERFERON_ALPHA_RESPONSE+0.280
- UNFOLDED_PROTEIN_RESPONSE+0.280
- NOTCH_SIGNALING+0.250
- OXIDATIVE_PHOSPHORYLATION+0.220
- ADIPOGENESIS+0.200
- GLYCOLYSIS+0.200
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- MYOGENESIS-0.400
- IL6_JAK_STAT3_SIGNALING-0.360
- COAGULATION-0.320
- ALLOGRAFT_REJECTION-0.290
- APICAL_SURFACE-0.290
- PANCREAS_BETA_CELLS-0.280
- TNFA_SIGNALING_VIA_NFKB-0.280
- INFLAMMATORY_RESPONSE-0.270
- KRAS_SIGNALING_DN-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-75-6207-01A-11R-1755-07 | — | cohortA1 | 0.900 |
| 2 | R128 | — | — | 0.869 |
| 3 | SRR1797241 | — | cohortSC | 0.858 |
| 4 | BS_EK5PCKY0 | Supratentorial Ependymoma | — | 0.841 |
| 5 | BS_H4NXBD2D | Supratentorial Ependymoma | — | 0.836 |
| 6 | BS_QXKRN6CR | Supratentorial Ependymoma | — | 0.834 |
| 7 | BS_QXKRN6CR | EPN | Supratentorial EPN | 0.828 |
| 8 | GSM5359428 | — | — | 0.827 |
| 9 | TCGA-DK-A3IS-01A-21R-A21D-07 | — | — | 0.824 |
| 10 | TCGA-4Z-AA80-01A-11R-A39I-07 | — | — | 0.821 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.440 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.280 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.280 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.250 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.160 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.130 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.110 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.030 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.030 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.010 | Idelalisib | — uncovered |